Study how effective and safe anifrolumab is in patients with hidradenitis suppurativa (HS).
This is a research study aims to determine if a drug called anifrolumab is safe and effective at treating hidradenitis suppurativa (HS). Anifrolumab is given via an intravenous (i.v.) infusion at UNC. You will have tests, exams and procedures for study purposes. Infusions of study drug will be given monthly, first at 900mg for three months, and then at 600mg for the next three months. Each month you will be evaluated, and you may be able to continue receiving anifrolumab if the study doctor determines that is safe for you to do so. Some visits will require you to fill out questionnaires, and for the study team to obtain a sample of your blood, assess your HS, obtain photographs of your HS, as well as electrocardiograms (EKG), which trace the electrical activity in your heart.
$150.00
Burnett-Womack Building (UNC-Chapel Hill)
160 Dental Cir, Chapel Hill, NC 27514, USA
Dermatology Clinical Trials Unit (DCTU)
UNC Dermatology and Skin Cancer Center at Southern Village
410 Market St Ste 362, Chapel Hill, NC 27516, USA
Chris Sayed
Dermatology-Research
Clinical or Medical
Interventional
Minority Health
Rare Diseases
Skin, Hair, and Nails
24-0191